#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Haemolytic uraemic syndrome HER2 gene amplification Autoinflammation with infantile enterocolitis Cardiac amyloidosis Metastases to central nervous system Small intestine leiomyosarcoma Salivary gland cancer Keratosis follicular Antisynthetase syndrome Multifocal motor neuropathy Nephroblastoma Infantile apnoea Retinopathy proliferative Oropharyngeal cancer recurrent Mantle cell lymphoma recurrent More trials…

    Learn about Rare Diseases

    Ewing’s sarcoma recurrent – Diagnostics Mastocytosis – Trials in Disease Mantle cell lymphoma stage III – Diagnostics Fabry’s disease – Basic Information Phenylketonuria – Diagnostics Andersen-Tawil syndrome – Diagnostics Alternating hemiplegia of childhood – Trials in Disease Osteosarcoma – Life with Disease Hereditary angioedema with C1 esterase inhibitor deficiency – Basic Information Wolfram syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Caffeine Bay 2927088 LY3841136 SODIUM Aluminium Oxide Doxecitine Iopamidol GLYCYL-TYROSINE Artemisia Vulgaris Nirogacestat Hydrobromide Dexrazoxane Hydrochloride Cariprazine Hydrochloride Istradefylline Isoprenaline Hydrochloride Golimumab Lacnotuzumab Lurasidone Zofenopril Calcium IBANDRONIC ACID Nimotuzumab AZD6234 More therapies…

    Learn about Your Condition

    Albright's disease Critical illness HER2 negative breast cancer Staphylococcal infection Contusion Schizophrenia Oxygen therapy Erythema migrans Left ventricular dysfunction Hand fracture Hip fracture Colorectal cancer stage II Apheresis Ectopic pregnancy Cleft lip and palate More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hepatitis B

  • Study on the Safety and Immune-Enhancing Effects of Pomalidomide in Patients with Chronic Hepatitis B Infection

    Recruiting

    1 1 1
    Investigated Diseases:
    • Hepatitis B
    Investigated Drugs:
    • Pomalidomide
    Denmark

  • Study on the Effects of Tobevibart and Elebsiran Compared to Bulevirtide for Patients with Chronic Hepatitis D Virus Infection

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hepatitis B
    • Hepatitis D
    Investigated Drugs:
    • Elebsiran
    • Tobevibart
    • Bulevirtide
    Belgium Bulgaria France Germany Italy The Netherlands +2

  • Study on Tobevibart and Elebsiran for Patients with Chronic Hepatitis D Virus Infection Not Responding to Bulevirtide Treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hepatitis B
    • Hepatitis D
    Investigated Drugs:
    • Elebsiran
    • Tobevibart
    • Bulevirtide
    Austria France Germany Italy Romania Spain

  • Study on Tobevibart and Elebsiran for Patients with Chronic Hepatitis D Virus Infection

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hepatitis B
    • Hepatitis D
    Investigated Drugs:
    • Elebsiran
    • Tobevibart
    France Germany Romania

  • Study on Bepirovirsen for Patients with HIV and Chronic Hepatitis B on Antiretroviral Treatment

    Not recruiting

    2 1
    France Italy Spain

  • Study on the Effects of VIR-2218 and VIR-3434 for Patients with Chronic Hepatitis D Infection

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Hepatitis B
    • Hepatitis D
    Investigated Drugs:
    • Elebsiran
    • Tobevibart
    Bulgaria France Germany Italy The Netherlands Romania
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!